OFFICE ADDRESS

Harper University Hospital Department of Pathology
3990 John R
Detroit, MI 48201
E-mail: rali@med.wayne.edu
Phone: (313) 966-6405

EDUCATION

Satah Hussari High School, Damascus, Syria. Graduated in 1983 with high honors. Class valedictorian.

Damascus University School of Medicine, Damascus, Syria. Graduated in 1989 with honors
(6 year combined undergraduate/graduate degree program).

POSTGRADUATE TRAINING

1989 – 1990 General Surgery Internship, Teshrin Teaching Hospital, Damascus, Syria

1991 – 1992 Pediatric Internship, Homburg University Hospital, Homburg, Saar, Germany

1995 – 1998 Residency Anatomic Pathology, University Hospitals of Cleveland,
Case Western Reserve University,
Cleveland, Ohio

1998- 2000 Fellowship
Obstetric-Gynecological Pathology, Detroit Medical Center - Hutzel
Hospital, Detroit, Michigan

2000- 2001 Fellowship
Cytopathology, Detroit Medical Center - Hutzel Hospital,
Detroit, Michigan

Other Training
1996 Surgical Pathology, one month, Elective rotation Henry Ford Hospital, Detroit, MI 1997 Molecular/research, one month, Elective rotation Henry Ford Hospital, Detroit, MI

2001 Cytopathology/GYN Pathology, two months, Elective rotation
MD Anderson Cancer Center, Houston, Texas

FACULTY APPOINTMENTS

2007 – present Associate Professor
Department of Pathology
Wayne State University School of Medicine
Karmanos Cancer Institute
Detroit, MI

2002 – 2006 Assistant Professor
Department of Pathology
Wayne State University School of Medicine
Karmanos Cancer Institute
Detroit, MI

HOSPITAL OR OTHER PROFESSIONAL APPOINTMENTS

1992 – 1994 General Practitioner and Primary Care Physician, Private practice setting, Damascus, Syria.

2001 – present Staff Pathologist, Detroit Medical Center
-Detroit Receiving Hospital
-Harper University Hospital
-Hutzel Hospital
-Karmanos Cancer Center

BOARD CERTIFICATION

Doctor of Medicine, Damascus University, Faculty of Medicine, 1989
Diplomat, American Board of Pathology, Anatomic Pathology, 2000

SERVICE

Patient Care

Surgical pathologist with subspecialty expertise in the area of gynecologic oncology pathology; primary activity at Harper University Hospital and the Karmanos Cancer Institute (responsible for sign out of approximately 2000 surgical pathology cases per year or 20 hours per week)

Consultant pathologist with responsibility for review of gynecologic oncology cases referred from outside institutions from throughout the State of Michigan (approximately 300 cases per year or 5 hours per week)

Member of the Karmanos Cancer Center Gynecologic Oncology Tumor Board responsible for review and presentation of pathology on patients referred to the team for second opinion and treatment of gynecologic malignancies (2 hours per week)

Membership on institutional committees

2000 – 2001 Cytopathology Quality Assurance Committee, Hutzel Hospital, Detroit Medical Center

2001 – 2003 Member of Karmanos Cancer Institute GYN oncology multidisciplinary team

2003 – present Director of the Tissue Procurement Program, GYN oncology, Wayne State University and the Karmanos Cancer Center

2003 – present Co-director of Karmanos Cancer Institute GYN oncology multidisciplinary team

2003 – present Member, Clinical faculty research working group

2004 – present Director of WSU Department of Pathology annual course (Contemporary Issues in Surgical Pathology – a full day CME program)

2004 – present Director of Pathology education, Department of Obstetrics and Gynecology

Regional and national professional service

2000 – present Member, Gynecologic Oncology Group (GOG, a NCI funded national clinical trials organization) Pathology Committee

2000 – present Central reviewer of pathology material for patients entered in GOG phase II and III clinical trials

2003 – present Ad-hoc reviewer, Gynecologic Oncology Journal

2005 – present Ad-hoc reviewer, Histology and Histopathology Journal

2006- present Scientific Committee member at the 28th National Medical Convention of the National Arab American Medical association

Community service

2003 - present Board member, National Arab-American Medical Association, Michigan Chapter.

2004 - present Chairperson of annual cancer Walk (NAAMA’s Walk for Women’s Cancer) Benefiting Karmanos Cancer Center

MAJOR PROFESSIONAL SOCIETIES

2000 – present International Obstetric and Gynecologic Society of Pathologists 2000 – present Michigan Society of Pathologists 1996 – present US-Canadian Association of Pathology (IAP) 1995 – present American Society of Clinical Pathologists 1995 – present College of American Pathologists
1993 – present National Arab-American Medical Association
1989 – present Syrian Syndicate of Medical Professionals

GRANT SUPPORT

Funding Agent (NCI) CA100740
Title: Markers for the Early Detection of Ovarian Cancer
P.I. TAINSKY, M.
Role in grant: Co-Investigator (10% effort): Responsible for review of medical records, histological analysis and classification of ovarian tumors and immunohistochemistry evaluation for novel tissue biomarkers.
Duration of grant 06/01/03 -05/30/08
Total cost of the entire period. $1,562,466

Funding Agent (Michigan Life Sciences Corridor) MLSC 538
Title: Assays for the Early Detection of Cancer
P.I. TAINSKY, M.
Role in grant: Co-Investigator (10% effort): Responsible for medical records review, histological analysis and classification of ovarian tumors and immunohistochemistry evaluation for novel tissue biomarkers.
Duration of grant 09/01/03 -08/31/07
Total cost of the entire period. $1,762,447

TEACHING

Wayne State University School of Medicine

1999 – 2000 Lecture, Basic Pathology Course (MS 4500): Pathologist Assistant Program, Wayne State University, School of Mortuary Sciences, Detroit, MI. Heart, Pulmonary, and OB-GYN Pathology, 1999-2000

1999 – present Lecturer (PTH 7500): Pathology for Nursing students, Wayne State University, School of Medicine. Female Reproductive System (4 contact hours + 8 hours prep time per year)

1999 – present Lecturer (IBS 7060): Pathology for PhD students, Wayne State University, School of Medicine. Female and Male Reproductive Systems (8 contact hours + 16 hours prep time per year).

2000 – present Instructing medical students rotating in the Department of Pathology, Harper University Hospital (approximately 100 contact hours per year)

2000 – present Lecturer, Pathophysiology Course, Second Year Medical Class, Pathology of the Breast (8 contact hours + 16 hours prep time per year)

2001 – present Instructor, Pathobiology Laboratory Units, Second Year Medical Class, (18 contact hours + 18 hours prep time per year).

2001 – present Instructor, Pathophysiology Laboratory Units, Second Year Medical Class, (20 contact hours + 20 hours prep time per year).

Wayne State University/Detroit Medical Center Pathology Residency Training Program

2001 – present Day to day teaching interactions with residents through frozen section and gross room supervision (average 1-2 contact hours per day)

2001 – present Formal didactic teaching sessions (12 contact hours + 12 hours prep time) in the areas of:

GYN-Oncology Pathology
Immunohistochemistry in Surgical Pathology: Diagnostic and Research Applications
Breast Pathology
Pap Smear in Cytopathology
Gross Surgical Pathology & Tissue acquisition protocols

2001 – present Mentoring of Residents and Fellows in research projects (80 – 120 hours per year). Residents and Fellows mentored: S Bandyopadhaya, I Khalifeh, V Pansare, E Pryor, H Nassar, S Khayyata, M Arabi.

Abstracts presented by Residents and Fellows as first author at national meetings: 16 (numbers 11, 12, 14, 15, 16, 17, 22, 23, 28, 31, 32, 33, 35, 36, 37 and 40 from ABSTRACTS)

First author publications by Residents and Fellows mentored: 3 (numbers 4, 7 and 12 from PUBLICATIONS)

Continuing Medical Education (CME) Teaching Activities – Institutional
Gynecologic Oncology Tumor Board, Harper Hospital - Hutzel Hospital, Detroit Medical Center, 1998-Present (1 hour per week).

Multi-disciplinary Breast Tumor Board, Harper Hospital, Detroit Medical Center,
2001-2002.

Lecture, Hematology-Oncology Fellow, Review Session, Ovarian Tumors, July, 2002.

Teaching Activities and Invited Lectures - Regional, National and International

“The Spectrum of Intraepithelial Endocervical Glandular Lesions,” The American University of Beirut, School of Medicine, Beirut, Lebanon, June 18, 1998.
“ Variants of endometrial carcinoma and its precursor lesions,” SEMCME, OB/GYN Board Review Course Pathology Session, Hutzel University Hospital, Detroit, Michigan, January 16, 2002.

“Prognostic factors in serous borderline tumor of the ovary,” Review of GYN Pathology, The American University of Beirut School of Medicine, Department of Pathology, Beirut, Lebanon, June 18, 2002.
“Prognostic factors in serous borderline tumor of the ovary,” Review of GYN Pathology, Damascus University School of Medicine, Department of Pathology, Damascus, Syria, June 25, 2002.
“ Review course: smooth muscle tumor of the uterus,” Review of GYN Pathology, Damascus University School of Medicine, Department of Pathology, Damascus, Syria, June 26, 2002.
“ Serous and other uncommon subtypes of endometrial carcinoma,” The American University of Beirut School of Medicine, Department of Pathology, Beirut, Lebanon, June 10, 2003.
“ Ovarian endometrioid tumors: benign, borderline and malignant,” The American University of Beirut School of Medicine, Department of Pathology, Beirut, Lebanon, June 11, 2003.
“ Serous and other uncommon subtypes of endometrial carcinoma,” Damascus University School of Medicine, Department of Pathology, Damascus, Syria, June 16, 2003.
“ Slide seminar: serous tumor of the ovary - benign, borderline and malignant,” Damascus University School of Medicine, Department of Pathology, Damascus, Syria, June 17, 2003.
“ Female Reproductive System,” Osler Institute of Pathology Board Review Course, November 2-8, 2003.

“Anatomy and histology of the uterine corpus” and “Benign and malignant disease of the endometrium,” SEMCME, OB/GYN Board Review Course Pathology Session, St. Johns Hospital, Detroit, Michigan, January 14, 2004.

“Type I vs. type II endometrial carcinoma,” Damascus University School of Medicine, Department of Pathology, Damascus, Syria, June 22, 2004.
“ The effect of cyclooxygenase-2 expression in GYN malignancy,” Damascus University School of Medicine, Department of Pathology, Damascus, Syria, June 23, 2004.

“ Current variants of endometrial carcinoma,” SEMCME, OB/GYN Board Review Course Pathology Session, Providence Hospital, Detroit, Michigan, January 12, 2005.

“Challenging cases in GYN-Pathology,” Contemporary Issues in Surgical Pathology, WSU-Pathology Course, Dearborn, Michigan, October 22, 2005.

PUBLICATIONS

Original Observations in Refereed Journals
1. Ali R, Massri G. Water resources in Northeast Syria and the risk for thyroid goiter, a statistical analysis and prevalence study. Damascus University Medical School Letters, Spring issue, 1990.
2. Ali R, Kaisi N, Al-Chaty E, Badin R, Pals G, Young C, Worsham M. Patterns of allelic loss at the BRCA1 locus in Arabic women with breast cancer. International Journal of Molecular Medicine 2000; 6:565-569.

3. Ali-Fehmi R, Carolin K, Wallis T, Visscher DW. Clinicopathologic analysis of breast lesions associated with multiple papillomas. Human Pathology 2003; 34:234-239.

4. Nassar H, Ali-Fehmi R, Madan S. Use of ThinPrep(R) monolayer technique and cytospin preparation in urine cytology: a comparative analysis. Diagnostic Cytopathology 2003; 28:115-118.

5. Ali-Fehmi R, Che M, Khalifeh I, Malone JM, Morris R, Lawrence WD, Munkarah AR. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Cancer 2003; 98(7):1423-1429.

6. Ali-Fehmi R, Qureshi F, Lawrence WD, Jacques S. Apoptosis, proliferation, and expression of P53 and BCL-2 in endocervical intraepithelial glandular lesions and invasive endocervical adenocarcinoma. Int J Gynecol Pathol 2004; 2:1-6, 2004

7. Khalifeh I, Munkarah AR, Lonardo F, Malone J, Morris R, Lawrence WD, Ali-Fehmi R. Expression of COX-2, CD34, Bcl-2 and p53 and survival in patients with peritoneal serous carcinoma and primary ovarian serous carcinoma. Int J Gynecol Pathol 2004; 23(2):162-169.

8. Sahin K, Ozercan R, Onderci M, Sahin N, Gursu MF, Khachik F, Sarkar FH, Munkarah A, Ali-Fehmi R, Kmak D, Kucuk O. Lycopene supplementation prevents the development of spontaneous smooth muscle tumors of the oviduct in Japanese quail. Nutr Cancer. 2004; 50:181-189.

9. Nassar H, Pansare V, Zhang H, Che M, Sakr W., Ali-Fehmi R, Grignon D, Sarkar F, Cheng J, Adsay NV. Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein. Modern Pathol 2004; 17:1045-1050.

10. Ali-Fehmi R, Morris R, Bandyotpadhyay S, Che M, Schimp V, Malone J, Munkarah AR. Expression of Cyclooxygenase-2 in Advanced Stage Ovarian Serous Carcinoma: Correlation
with Tumor Cell Proliferation, Apoptosis, Angiogenesis, and Survival. Am J Obstet Gynecol. 2005; 192:819-25.

11. Munkarah AR. Ali-Fehmi R. COX-2: A Protein with an Active Role in Gynecologic Cancers. Curr Opin Obstet Gynecol. 2005; 17(1):49-53.

12. Khalifeh I, Munkarah AR, Schimp V, Malone JM, Morris R, Lawrence WD, Ali-Fehmi R. Low Expression of C-kit is Associated with High Expression of Ki-67 and Poor Prognosis in Advanced Ovarian Serous Carcinoma. Int J Gynecol Pathol. 2005; 24:228-34.

13. Ali-Fehmi R, Khalifeh I, Bandyopadhyay S, Lawrence WD, Silva EG, Liao J, Sarkar F, Munkarah AR,. Patterns of loss of hetrozygosity (LOH) at 10q123.3 and microsatellite instability (MSI) in ovarian endometriosis, atypical endometriosis and epithelial carcinoma arising in a background of endometriosis. Int J Gynecol Pathol 2006; 25:223-229.

14. Solomon LA, Schimp VL, Ali-Fehmi R, Diamond MP, Munkarah AR. Clinical update of smooth muscle tumors of the uterus. Journal of the AAGL, J Minim Invasive Gynecol. 2005; 12(5):401-408.

15. Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, Wang X, Nowak J, Ye B, Nahhas FA, Lu K, Witkin SS, Fishman D, Munkarah A, Morris R, Levin NK, Shirley NN, Tromp G, Abrams J, Draghici S, Tainsky MA. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res. 2006; 66:1181-1190.

16. Shen X-J, Ali-Fehmi R, Weng C-R, Sarkar F, Grignon D, and Liao JD. Loss of heterozygosity and microsatellite instability at the Xq28 and the A/G heterozygosity of the QM gene are associated with ovarian cancer. Cancer Biol Ther. 2006; 5:523-528

17. Solomon LA, Munkarah AR, Schimp VL, Arabi MH, Morris RT, Nassar H, Ali-Fehmi R, . Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. Gynecol Oncol. 2006; 101:385-389.

18. Schimp VL, Ali-Fehmi R, Solomon LA, Hammoud A, Pansare V, Morris RT, Munkarah AR. The racial disparity in outcomes in endometrial cancer: could this be explained on a molecular level? Gynecol Onc. 2006 Sep;102(3):440-6.

19. Saed GM, Ali-Fehmi R, Munkarah AR, Diamond MP. Adhesion phenotype: Profiling of fibroblasts isolated from human normal peritoneal and adhesion tissues using apoptosis gene arrays. Fert Stert. (12/2005, Submitted and under review – receipt letter appended).

20. Saed GM, Ali-Fehmi R, Deppe G, Malone JM Jr, Munkarah AR. Inhibition of Ovarian Cancer Induced Angiogenesis by the Inhibition of Cyclo-Oxygenase. Gynecol Oncol (02/2006, submitted and under review – receipt letter appended)

21. Munkarah AR, Ali-Fehmi R, Elhammady E, Malone JM Jr, Saed GM. The effects of inhibitors in epithelial ovarian cancer. Anti-Cancer Drugs (submitted Oct 2006).

22. Pansare V, Munkarah AR, Schimp V, Haitham Arabi M, Saed GM, Morris RT, Ali-Fehmi R. Increased expresión of hypoxia-inducible factor 1alpha in type I and type II endometrial carcinomas. Mod Pathol. 2007 Jan;20(1):35-43.

23. Munkarah AR, Ali-Fehmi, R, Jiang JZ, Elhammady E, Malone JM Jr., Saed GM. The effects of combining docetaxel and COX-2 inhibitors on proliferation and apoptosis in epithelial ovarian cancer. Anti-Cancer Drugs. (In Press).

Book Chapters, Review Articles, Other Non-Refereed
1. Ali R, Kotob F, Tomoke S. A comprehensive approach to understanding pain and its management. Doctoral dissertation. Damascus University Publications, 1989.

2. Ali R, Jacques S. Yolk sac tumor in the testis, a case review and discussion. Society of Pediatric Pathology-Slide Survey. Fourth quarter 1998.

3. Munkarah AR, Ali-Fehmi R, Role of Immunohistochemical Expression of Cyclooxygenase-2 in Ovarian Serous Carcinoma, Handbook of Immunochemistry and in situ Hybridization of Human Carcinomas, Volume 4: Molecular Genetics, Gastrointestinal Carcinoma, and Ovarian Carcinoma, Elsevier (USA), 2006

PUBLISHED ABSTRACTS

1.Ali R, Qureshi F, Lawrence WD, and Jacques SM. Apoptosis, proliferation, and expression of P53 and Bcl-2 in endocervical intraepithelial glandular lesions and invasive endocervical adenocarcinoma. Annual Meeting of US-Canadian Academy of Pathology, San Francisco, CA, March 1999.

2. Ali R, Qureshi F, Jacques SM, and Lawrence WD. Karmanos Cancer Institute/Wayne State University School of Medicine, Detroit, MI. Expression of P27/kip1 and Ki-67 in benign endocervix and intraepithelial and invasive endocervical glandular lesions. Annual Meeting of US-Canadian Academy of Pathology, San Francisco, CA, March 1999.

3. Ali R, Weisner G, Al-Kaisi N, Zaatari G, Chatty E, Warsham M. Loss of heterozygosity (LOH) of BRCA1 in Arabic women with breast cancer. Multidisciplinary Symposium on Breast Cancer, 4th Annual Meeting, February 11-14, 1999.

4.Worsham M, Ali R, Pals G. Ethnic differences in breast cancer susceptibility. The 2nd Biannual Meeting of the Asian Breast Cancer Society September 2-3 1999.

5.Jolly S, Ali R, Visscher D, Lawrence WD. DNA ploidy analysis of endocervical glandular intraepithelial and invasive lesion using DNA image cytometry. Modern Pathology 2000, United States and Canadian Academy of Pathology. 89th Annual meeting. March 20-26, 2000.

6. Ali-Fehmi R, Phadke D, and Madan S. Use of Thin Prep7 Monolayer Technique and cytospin preparation in urine cytology, A comparative analysis. Modern Pathology 266 United States and Canadian Academy of Pathology. 90th Annual meeting. March 4-7, 2000.

7.Visscher D, Ali-Fehmi R, Wallis T and Lawrence WD. Histologic analysis of
multiple papillomas of the breast. Modern Pathology 217, United States and
Canadian Academy of Pathology. 90th Annual meeting. March 4-7, 2000

8. Ali-Fehmi R, Munkarah AR, Che M, Bandyopadhyay S, Malone JM, Lawrence WD. Prognostic tumor makers in ovarian serous carcinoma (SOC): A study of one hundred and twenty five advanced stage cases. Modern Pathology 15(1):179A, 2003.

9. Ali-Fehmi R, Bandyopadhyay S, Munkarah AR, Lawrence WD, Silva EG. Angiogenesis and the expression of COX-2, BCL-2 and P53 in ovarian endometriosis, atypical endometriosis and epithelial carcinoma arising in a background of endometriosis. Modern Pathology 15(1):180A, 2003.

10. Ali-Fehmi R, Silva E, Sakr W, Lucas D, Che M, Dey J, Adsay V. The challenge in distinguishing metastatic ovarian and pancreatobiliary carcinoma in the abdomen and the morphologic criteria for their distinction. Modern Pathology 15(1):180A, 2003.

11.Bandyopadhyay S, Ali-Fehmi R, Munkarah AR, Lawrence WD, Silva EG. Comparison of E-cadherin expression in eutopic endometrium, adenomyosis, endometriosis, atypical endometriosis and ovarian carcinoma arising in endometriosis. Modern Pathology 15(1):182A, 2003.

12.Bandyopadhyay S, Ali-Fehmi R, Munkarah AR, Silva EG, Sarkar F. Patterns of loss of hetrozygosity (LOH) at 10q123.3 and microsatellite instability (MSI) in ovarian endometriosis, atypical endometriosis and epithelial carcinoma arising in a background of endometriosis. Modern Pathology 15(1):182A, 2003.

13.Black M, Ali R, Stringer A, Deavers MT, Malpica A, Silva EG. Uterine adenomyosis, complete and incomplete. Modern Pathology 15(1):182A, 2003.

14.Khalifeh I, Ali-Fehmi R, Bandynopadhyay S, Munkarah AR, Morris R, Lawrence WD. Expression of COX-2, CD34, BCL-2 and P-53 and survival in patients with primary peritoneal serous carcinoma (PPC) in comparison to primary serous carcinoma (OSC). Modern Pathology 15(1):195A, 2003.

15.Pansare V, Ali-Fehmi R, Lawerence WD, Morris R, Munkarah AR. Angiogenesis, Cyclooxygenase-2 and P53 expression in borderline, low grade
and high grade ovarian epithelial neoplasms. Modern Pathology 15(1):204A, 2003.

16.Pryor E, Ali-Fehmi R, Munkarah AR, Lawrence WD. COX-2 and KI-67 protein expression and angiogenesis in ovarian granulosa cell tumors. Modern Pathology 15(1):206A, 2003.

17.Nassar H, Pansare V, Zhang H, Kotcher G, Che M, Sakr W, Ali-Fehmi R, Grignon D, Sarkar F, Cheng J, Adsay NV. Reverse polarization of cells with expression of MUC1 in the stroma-facing surfaces may be a key factor in the pathogenesis and morphogenesis of invasive micropapillary carcinoma. Modern Pathology 15(1):298A, 2003

18.Morris R, Ali-Fehmi R, Baker V, Jacques S, Qureshi F, Malone J, Munkarah AR. A comparison of molecular characteristics and survival among women with advanced stage epithelial ovarian cancer. Journal of the Society for Gynecology Investigation 10(2):454, 2003.

19. Munkarah AR, Zhu G, Ali-Fehmi R, Morris R, Malone JM, Diamond MO, Saed GM. Short-term treatment of Epithelial ovarian Cancer Cells with the COX-2 Inhibitor, NS398, results in Downregulation of Expression of Vascular Endothelial growth Factor VEGF. Presented at the 94th AACR Annual Meeting, Proceedings, p346, #5864, 2003.

20.Schimp VL, Ali-Fehmi R, Baker VV, Solomon LA, Deppe G, Munkarah AR, Kazzi M. Molecular Characteristics of Endometrial Carcinoma by Ethnicity. Society for Gynecologic Investigation. Presented at the 51st SGI Annual meeting, #990, 2004.

21.Hammoud AO, Ali-Fehmi R, Schimp V, Deppe G, Kazzi M, Malone J, Munkarah AR. HIF 1a Expression in Endometrioid Carcinoma: Tumor Biology and Prognosis. Society for Gynecologic Investigation, Presented at the 51st SGI Annual meeting, #974, 2004.

22.Pansare VM, Ionescu MC, Halloush R, Hammoud A, Munkarah AR, Lawrence WD, Ali-Fehmi R. Increased Expression of HIF-1 in Type II Endometrial Carcinomas. Modern Pathology 17(1):210A, 2004.

23.Khalifeh I, Bandyopadhyay S, Malone J, Munkarah AR, Lawrence WD, Ali-Fehmi R. Low expression of C-kit associated with high expression of Ki-67 and poor prognosis in advance ovarian serous carcinoma (SOC).Modern Pathology 17(1):199A, 2004.

24. Ali-Fehmi R, Nassar H, Pansare V, Bandyopadhyay S, Sarkar F, Munkarah AR, Liao J. QM Gene Expression in normal ovary and in serous ovarian carcinoma. Modern Pathology 17(1):189A, 2004

25.Ali-Fehmi R, Ahmad O, Hammoud A, Bandyopadhyay S, Malone J, Deppe G, Morris R, Munkarah AR. Expression of Cyclooxygenase-2 in Advanced Stage Ovarian Serous Carcinoma: Correlation with Tumor Cell Proliferation, Apoptosis, Angiogenesis and Survival, Soc of Gynecol Oncologists 92(1)400, #15, 2004.

26.Hammoud AO, Ali-Fehmi R, Baker VV, Metcalfe N, Deppe G, Munkarah AR. Effect of Thrombocytosis on Tumor Angiogenesis and Patient Survival in Epithelial Ovarian Cancer. Soc of Gynecol Oncologists 92(1)493,#223, 2004.

27.Che M, Singh RS, Khayyata SH, Ali-Fehmi R, Sakr W, Grignon D. Alteration of Prognostic Value of COX-2 in Prostate Cancer by Maspin. Modern Pathology 18(1):132A, 2005.

28.Khayyata SH, Singh RS, Ali-Fehmi R, Sakr W, Grignon D, Che M. Intratumoral Vascularity in Transurethral Resection Predicts Bladder Carcinoma Metastasis. Modern Pathology 18(1):149(A), 2005.

29. Ali-Fehmi R, Dean S, Arabi MH, Lonardo F, Che M, Abdul-Karim FW, Munkarah AR. Maspin Expression in Serous Endometrial Carcinoma: Its Relationship with Angiogenesis and Clinicopathologic Outcome. Modern Pathology 18(1):176(A), 2005.

30. Ali-Fehmi R, Nassar H, Che M, Munkarah AR, Silva E. Mixed Serous-Endometrioid Carcinoma of the Uterus. Modern Pathology 18(1):177(A), 2005.

31. Arabi MH, Bandyopadhyay S, Fathallah L, Nassar H, Mujtaba H, Ali-Fehmi R. Expression of COX-2, VEGF, Ki-67 and p53, in Squamous Cervical Neoplasia. Modern Pathology 18(1):177(A), 2005.

32. Bandyopadhyay S, Arabi MH, Nassar H, Fleshman R, Abdul-Karim FW, Munkarah AR, Ali-Fehmi R. The Presence of a Malignant Polyp in Advanced Uterine Serous Carcinoma is Associated with a Significantly Worse Prognosis. Modern Pathology 18(1):178(A), 2005.

33. Nassar H, Arabi MH, Bandyopadhyay S, Munkarah A, Ali-Fehmi R. Expression of COX2 in Uterine Serous Carcinoma. Modern Pathology 18(1):179(A), 2005.

34. Ali-Fehmi R, Basturk O, Cheng JD, Khalifeh I, Bandyopadhyay S, Silva E, Nassar H, Adsay NV. Immunohistochemistry as a Helpful Adjunct in the Differential Diagnosis of Intraabdominal Carcinomatosis Originating from the Pancreas Versus Ovary. Modern Pathology 18(1):273(A), 2005.

35. M.H. Arabi , H. Nassar , A. Munkarah , R. Morris , V.L. Schimp, L.A.Solomon , and R. Ali-Fehmi , Maspin Expression in Advanced Stage Ovarian Serous Carcinoma: Its Relationship with Angiogenesis, COX-2 Expression and Clinicopathologic Outcome. Am J Clin Pathol 2005;124:625-660.

36. M H Arabi , H Nassar, S Dean , J Feng , M Husain, F W Abdul-Karim, A Munkarah and R Ali-Fehmi, Pap Smear in Type I and Type II Endometrial Carcinoma. Am J Clin Pathol 2005;124:625-660.

37. H. Nassar , M.H. Arabi , V.L. Schimp , A. Hammoud , L.A. Solomon, V. Pansare , A. Munkarah , and R. Ali-Fehmi, Molecular Characteristics of Endometrial Carcinoma by Ethnicity. Am J Clin Pathol 2005;124:625-660.

38. R. Ali-Fehmi, M. Chatterjee, S. Mohapatra, M.H. Arabi , A. Munkarah, R. Morris, N. K. Levin , N. N. Victor, and M. A. Tainsky. High Throughput Cloning of Ovarian Cancer-related Antigens and their Efficacy as Tissue Biomarkers. Am J Clin Pathol 2005;124:625-660.

39. Ali-Fehmi R, Ghassan S, Schimp V, Solomon LA, Malone J, and A. R. Munkarah Overexpression of iNOS in ovarian serous carcinomas is associated with increased angiogenesis. Proc Amer Assoc Cancer Res 2005;46:[4642], 2005.

40. S Bandyopadhyay, V Pansare, J Feng, R Ali-Fehmi, R Bhan, M Husin, MA Al-Abbadi. The Frequency and Rationale of Fine Needle Aspiration Biopsy Conversion to Core Biopsy as a Result of Onsite Evaluation. Modern Pathology 19(1):53(A), 2006.

40. Ali-Fehmi R Cote M, Solomon LA, Schimp V, Morris R, Munkarah A. Leiomyosarcoma of the uterus: A population-based analysis. Society of Gynecologic Oncologists 2006 Annual Meeting (poster).

41. Ali-Fehmi R, Cote M, Solomon LA, Schimp V, Morris R, Munkarah A. Leiomyosarcoma of the uterus: A population-based analysis. Society of Gynecologic Oncologists 2006 Annual Meeting (poster).

42. Schimp VL, Bryant CS, Solomon LA, Hannah R, Ali-Fehmi R, Morris RT, Munkarah AR. Impact of ethnicity on survival among African American patients with epithelial ovarian cancer. Society of Gynecologic Oncologists 2006 Annual Meeting (poster).

43. Munkarah AR, Ali-Fehmi R, Malone J, Deppe G, Saed G. Knock-out of iNOS reduced VEGF production and angiogenesis in epithelial ovarian cancer cell lines. Society of Gynecologic Oncologists 2006 Annual Meeting (poster).